A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis.

MLA

van der Vegt, Solveig A., et al. “A Model-Informed Approach to Assess the Risk of Immune Checkpoint Inhibitor-Induced Autoimmune Myocarditis.” Frontiers in Pharmacology, vol. 13, Sept. 2022, pp. 1–16. EBSCOhost, https://doi.org/10.3389/fphar.2022.966180.

APA

van der Vegt, S. A., Ying-Jie Wang, Polonchuk, L., Ken Wang, Waters, S. L., & Baker, R. E. (2022). A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis. Frontiers in Pharmacology, 13, 1–16. https://doi.org/10.3389/fphar.2022.966180

Chicago

van der Vegt, Solveig A., Ying-Jie Wang, Liudmila Polonchuk, Ken Wang, Sarah L. Waters, and Ruth E. Baker. 2022. “A Model-Informed Approach to Assess the Risk of Immune Checkpoint Inhibitor-Induced Autoimmune Myocarditis.” Frontiers in Pharmacology 13 (September): 1–16. doi:10.3389/fphar.2022.966180.